A retrospective study of apatinib plus drug-eluting bead transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization alone in treating huge hepatocellular carcinoma patients
Latest Information Update: 06 Dec 2022
At a glance
- Drugs Rivoceranib (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 06 Dec 2022 New trial record
- 01 Dec 2022 Results published in the Irish Journal of Medical Science